Eric L Smith

This inventor holds 88 USPTO granted patents and 40 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Chimeric Antigen Receptors (CPC class C07K2317-31). Top assignees: Regeneron Pharmaceuticals, Inc., Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.. Active years: 1982-2026.

USPTO Granted Patents = 88 (Patent Applications = 40)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 11)

EPO Patents = 5 (Patent Applications = 13)

Average Co-Inventor Count = 3.8

ph-index = 14

Forward Citations = 921(Granted Patents)

Forward Citations (Not Self Cited) = 811(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Hagerstown, MD (US) (1982 - 1994)
North Richland Hills, TX (US) (1999)
Sarver, PA (US) (2015)
New York, NY (US) (2009 - 2024)

Company Filing History:

56 out of 1,471

Regeneron Pharmaceuticals, Inc.

patents

19 out of 615

Memorial Sloan Kettering Cancer Center

patents

17 out of 52

Eureka Therapeutics, Inc.

patents

4. 6 out of 49

Regeneran Pharmaceuticals, Inc.

patents

5. 2 out of 77

Juno Therapeutics Gmbh

patents

6. 4 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1982-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

Bispecific Antibodies

Cytokine Release Syndrome

Nucleic Acid Molecules

Tumor Treatment

Anti-PSMA Antibodies

IL2 Agonists

Antigen Binding Molecules

Humanized CD3 Complex

Multi-Specific Antigen-Binding

IgG Fc Fusions

Heavy Chain Constant Regions

88 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655211 - ANTIBODIES TARGETING G-PROTEIN COUPLED RECEPTOR AND METHODS OF USE (2026-06-16),

2. 12636375 - Antibodies targeting Fc receptor-like 5 and methods of use (2026-05-26),

3. 12473345 - METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN (2025-11-18),

4. 12428486 - Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides (2025-09-30),

5. 12391753 - Antigen binding molecule formats (2025-08-19),

6. 12344677 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof (2025-07-01),

7. 12331109 - Antigen binding molecule formats (2025-06-17),

8. 12319724 - IL2 agonists and methods of use thereof (2025-06-03),

9. 12274747 - Compositions and methods for treating cytokine release syndrome (2025-04-14),

10. 12258412 - Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies (2025-03-25),

11. 12215148 - Antigen binding molecule formats (2025-02-04),

12. 12215131 - IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof (2025-02-04),

13. 12180272 - Antigen binding molecule formats (2024-12-31),

14. 12157758 - Readily isolated bispecific antibodies with native immunoglobulin format (2024-12-03),

15. 12139538 - Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof (2024-11-12),

Title: The Inventor Profile of Eric L Smith

Introduction: Eric L Smith is a prolific inventor based in New York, NY, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Eric L Smith holds several patents in diverse areas such as technology, healthcare, and consumer products, showcasing his versatility and creativity in inventing novel solutions to complex problems.

Career Highlights: With a career spanning over two decades, Eric L Smith has established himself as a leading figure in the world of innovation, with numerous successful inventions that have had a significant impact on industries worldwide.

Collaborations: Throughout his career, Eric L Smith has collaborated with top research institutions, universities, and companies to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Eric L Smith's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor, shaping the future of technology and beyond.